FR10C0038I1 - - Google Patents

Info

Publication number
FR10C0038I1
FR10C0038I1 FR10C0038C FR10C0038I1 FR 10C0038 I1 FR10C0038 I1 FR 10C0038I1 FR 10C0038 C FR10C0038 C FR 10C0038C FR 10C0038 I1 FR10C0038 I1 FR 10C0038I1
Authority
FR
France
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
Other languages
French (fr)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Medivir AB
Original Assignee
Medivir AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medivir AB filed Critical Medivir AB
Publication of FR10C0038I1 publication Critical patent/FR10C0038I1/fr
Application granted granted Critical
Publication of FR10C0038I2 publication Critical patent/FR10C0038I2/fr
Active legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biotechnology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
FR10C0038C 1995-02-06 2010-08-17 Active FR10C0038I2 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9500114 1995-02-06
PCT/SE1996/000124 WO1996024355A1 (en) 1995-02-06 1996-02-02 Novel pharmaceutical combination

Publications (2)

Publication Number Publication Date
FR10C0038I1 true FR10C0038I1 (zh) 2010-10-15
FR10C0038I2 FR10C0038I2 (zh) 2011-04-29

Family

ID=20396821

Family Applications (1)

Application Number Title Priority Date Filing Date
FR10C0038C Active FR10C0038I2 (zh) 1995-02-06 2010-08-17

Country Status (30)

Country Link
US (2) US6337324B1 (zh)
EP (2) EP0809498B1 (zh)
JP (2) JP4260220B2 (zh)
KR (1) KR100431042B1 (zh)
CN (1) CN1131034C (zh)
AR (1) AR002030A1 (zh)
AT (2) ATE421358T1 (zh)
AU (1) AU716809B2 (zh)
CA (1) CA2211389C (zh)
DE (3) DE69637828D1 (zh)
DK (1) DK0809498T3 (zh)
DZ (1) DZ1966A1 (zh)
ES (1) ES2214528T3 (zh)
FI (1) FI119415B (zh)
FR (1) FR10C0038I2 (zh)
HK (1) HK1004368A1 (zh)
HR (1) HRP960034B1 (zh)
IL (1) IL116913A0 (zh)
MA (1) MA23800A1 (zh)
MY (1) MY119365A (zh)
NO (1) NO314220B1 (zh)
NZ (1) NZ301407A (zh)
PT (1) PT809498E (zh)
SA (1) SA96160590B1 (zh)
SI (1) SI0809498T1 (zh)
TN (1) TNSN96024A1 (zh)
TW (1) TW438585B (zh)
WO (1) WO1996024355A1 (zh)
YU (1) YU49477B (zh)
ZA (1) ZA96527B (zh)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9601544D0 (en) 1996-01-26 1996-03-27 Smithkline Beecham Plc Pharmaceuticals
IT1287114B1 (it) * 1996-10-31 1998-08-04 Recordati Chem Pharm Composizioni farmaceutiche antierpetiche per applicatori topici, contenenti aciclovir
SE9803929D0 (sv) * 1998-11-18 1998-11-18 Medivir Ab Antiviral formulation
US7223387B2 (en) 1998-11-18 2007-05-29 Medivir Ab Antiviral formulations comprising propylene glycol and an isopropyl alkanoic acid ester
US7655252B2 (en) 1999-04-28 2010-02-02 The Regents Of The University Of Michigan Antimicrobial nanoemulsion compositions and methods
US7767216B2 (en) * 1999-04-28 2010-08-03 The Regents Of The University Of Michigan Antimicrobial compositions and methods of use
FR2837102B1 (fr) * 2002-03-18 2004-10-08 Palbian Snc Composition a l'etat de gel aqueux, procede de fabrication et utilisation pour la fabrication d'un medicament, notamment antiherpetique
US20040023935A1 (en) * 2002-08-02 2004-02-05 Dey, L.P. Inhalation compositions, methods of use thereof, and process for preparation of same
US20040109826A1 (en) * 2002-12-06 2004-06-10 Dey, L.P. Stabilized albuterol compositions and method of preparation thereof
US20050208083A1 (en) * 2003-06-04 2005-09-22 Nanobio Corporation Compositions for inactivating pathogenic microorganisms, methods of making the compositons, and methods of use thereof
JP2007504123A (ja) * 2003-08-29 2007-03-01 ランバクシー ラボラトリーズ リミテッド Ｉｖ型ホスホジエステラーゼの阻害剤
US20070259874A1 (en) * 2003-11-26 2007-11-08 Palle Venkata P Phosphodiesterase Inhibitors
US7618950B2 (en) * 2004-07-07 2009-11-17 Arigen Pharmaceuticals, Inc. Method for treatment and prevention of herpes zoster by topical application
EP1865960A2 (en) * 2005-03-30 2007-12-19 Novartis AG Penciclovir or famciclovir for the treatment of recurrent genital herpes with a one-day application
CA2604392A1 (en) * 2005-04-11 2006-10-19 Nanobio Corporation Quaternary ammonium halides for treatment of infectious conditions
WO2008051186A2 (en) * 2005-08-09 2008-05-02 Nanobio Corporation Nanoemulsion containing compositions having ant i -inflammatory activity
WO2007031838A1 (en) 2005-09-16 2007-03-22 Ranbaxy Laboratories Limited Substituted pyrazolo [3,4-b] pyridines as phosphodiesterase inhibitors
US7797337B2 (en) * 2005-09-29 2010-09-14 Scenera Technologies, Llc Methods, systems, and computer program products for automatically associating data with a resource as metadata based on a characteristic of the resource
US20090221664A1 (en) 2005-10-19 2009-09-03 Abhijit Ray Pharmaceutical compositions of muscarinic receptor antagonists
WO2007045980A1 (en) * 2005-10-19 2007-04-26 Ranbaxy Laboratories Limited Compositions of phosphodiesterase type iv inhibitors
FR2900577B1 (fr) * 2006-05-04 2008-09-12 Goemar Lab Sa Nouveaux medicaments pour les traitements contre le virus de l'herpes
WO2008035316A2 (en) * 2006-09-22 2008-03-27 Ranbaxy Laboratories Limited Phosphodiesterase inhibitors
US20110021473A1 (en) * 2006-09-22 2011-01-27 Ranbaxy Laboratories Limited Inhibitors of phosphodiesterase type-iv
US20080207659A1 (en) * 2007-02-15 2008-08-28 Asit Kumar Chakraborti Inhibitors of phosphodiesterase type 4
US20110130403A1 (en) * 2007-03-14 2011-06-02 Ranbaxy Laboratories Limited Pyrazolo [3, 4-b] pyridine derivatives as phosphodiesterase inhibitors
MX2009009793A (es) 2007-03-14 2009-10-16 Ranbaxy Lab Ltd Derivados de pirazolo (3,4-b) piridina como inhibidores de fosfodiesterasa.
EP2155209A4 (en) * 2007-04-26 2012-06-13 Univ Pennsylvania DNA polymerase inhibitor composition and method
WO2008137747A1 (en) 2007-05-02 2008-11-13 The Regents Of The University Of Michigan Nanoemulsion therapeutic compositions and methods of using the same
JP4972062B2 (ja) * 2008-03-17 2012-07-11 メディヴィル・アクチエボラーグ 抗ウイルス製剤
EP2111861A1 (en) 2008-04-21 2009-10-28 Ranbaxy Laboratories Limited Compositions of phosphodiesterase type IV inhibitors
US20090291895A1 (en) * 2008-05-23 2009-11-26 Wong Scott W Methods and Compositions for the Treatment of Inflammatory Diseases
WO2011035120A2 (en) * 2009-09-17 2011-03-24 Gk Ventures, L.L.C. Therapeutic composition to treat lesions caused by herpes simplex virus
CN102049050B (zh) * 2009-11-02 2014-06-18 重庆华邦制药有限公司 抗疱疹病毒感染的药物组合物
EP2489354A1 (en) * 2011-02-18 2012-08-22 Vironova AB Pharmaceutical formulation of B220 for topical treatment of herpes
ITMI20111747A1 (it) * 2011-09-28 2013-03-29 Fidia Farmaceutici Composizioni farmaceutiche topiche comprendenti aciclovir
FR2983731B1 (fr) * 2011-12-07 2014-04-25 Univ Paris Descartes Emulsions topiques a base de melanges eutectiques d'anesthesiques locaux et d'acide gras
US10682370B2 (en) 2013-03-13 2020-06-16 Nal Pharmaceutical Group Limited Topical antiviral composition containing a local anesthetic and method of making the same
CN104324039A (zh) * 2014-10-20 2015-02-04 付茜 一种治疗人身体表面脂肪瘤的药剂及使用方法
CN108853140A (zh) * 2018-07-18 2018-11-23 豆立忠 一种多药物模块软膏及其制备方法
ES2955089T3 (es) * 2018-08-17 2023-11-28 Ilko Ilac Sanayi Ve Ticaret Anonim Sirketi Composición tópica estable en fase que comprende aciclovir e hidrocortisona
CN114302707A (zh) 2019-06-14 2022-04-08 普洛拉治疗公司 局部阿昔洛韦制剂及其用途
CN112569243A (zh) * 2019-09-30 2021-03-30 神农医药科技有限公司 制备治疗阿尔茨海默病的药物
WO2021231499A2 (en) * 2020-05-11 2021-11-18 Revir, Inc. Compositions and methods for treating viral infections
CN112704154A (zh) * 2020-12-24 2021-04-27 中国人民解放军66399部队 一种用于治疗宠物猫疱疹病毒的营养膏
US11951082B2 (en) * 2022-08-22 2024-04-09 Ford Therapeutics, Llc Composition of chlorhexidine

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3317384A (en) * 1964-06-08 1967-05-02 Upjohn Co Treatment of topical viral infections with glucocorticoids and nucleosides
US4512978A (en) * 1980-01-24 1985-04-23 Inwood Louis R Dermatological composition useful in the treatment of psoriasis
US4902678A (en) * 1982-02-12 1990-02-20 Syntex (U.S.A.) Inc. Anti-viral compositions
US4610868A (en) * 1984-03-20 1986-09-09 The Liposome Company, Inc. Lipid matrix carriers for use in drug delivery systems
US5223263A (en) 1988-07-07 1993-06-29 Vical, Inc. Liponucleotide-containing liposomes
EP0594224A3 (en) * 1985-09-17 1994-07-13 Wellcome Found Therapeutic nucleosides
US4942031A (en) 1988-02-23 1990-07-17 Levin Robert H Compositions containing LYCD and other topically active medicinal ingredients
US5023090A (en) 1989-08-16 1991-06-11 Levin Robert H Topical compositions containing LYCD and other topically active medicinal ingredients for the treatment of ACNE
WO1990006775A1 (en) * 1988-12-14 1990-06-28 Liposome Technology, Inc. A novel nonphospholipid liposome composition for sustained release of drugs
AU636255B2 (en) * 1990-11-05 1993-04-22 Arthropharm Pty Ltd Use of a topical formulation for the treatment of viral infections and neoplastic disorders
US5856364A (en) * 1991-03-01 1999-01-05 Warner Lambert Company Therapeutic antiviral-wound healing compositions and methods for preparing and using same
AU666852B2 (en) 1991-05-01 1996-02-29 Henry M. Jackson Foundation For The Advancement Of Military Medicine A method for treating infectious respiratory diseases
IL104283A (en) * 1992-12-30 1996-12-05 Agis Ind 1983 Ltd Non-emulsion antiviral topical pharmaceutical composition comprising acyclovir an aqueous gel agent and an alkali oleate
GB9315755D0 (en) * 1993-07-30 1993-09-15 Wellcome Found Stabilized formulation
DZ1965A1 (fr) * 1995-02-06 2002-07-17 Astra Ab Composition pharmaceutique nouvelle.
GB9601544D0 (en) 1996-01-26 1996-03-27 Smithkline Beecham Plc Pharmaceuticals

Also Published As

Publication number Publication date
DE122010000032I1 (de) 2010-10-21
CN1131034C (zh) 2003-12-17
NZ301407A (en) 1999-01-28
ATE262907T1 (de) 2004-04-15
EP1419803A3 (en) 2004-06-09
SI0809498T1 (en) 2004-12-31
FI973243A0 (fi) 1997-08-06
FR10C0038I2 (zh) 2011-04-29
DK0809498T3 (da) 2004-05-10
AU4682196A (en) 1996-08-27
DE69632034T2 (de) 2004-10-14
DE69632034D1 (de) 2004-05-06
JPH11506417A (ja) 1999-06-08
HRP960034B1 (en) 2002-02-28
USRE39264E1 (en) 2006-09-05
SA96160590B1 (ar) 2005-10-05
TNSN96024A1 (fr) 2005-03-15
EP1419803A2 (en) 2004-05-19
NO314220B1 (no) 2003-02-17
ATE421358T1 (de) 2009-02-15
DZ1966A1 (fr) 2002-10-15
TW438585B (en) 2001-06-07
JP4260220B2 (ja) 2009-04-30
FI973243A (fi) 1997-08-06
CA2211389A1 (en) 1996-08-15
FI119415B (fi) 2008-11-14
ZA96527B (en) 1996-08-06
NO973612D0 (no) 1997-08-05
MY119365A (en) 2005-05-31
YU49477B (sh) 2006-05-25
EP0809498B1 (en) 2004-03-31
ES2214528T3 (es) 2004-09-16
AU716809B2 (en) 2000-03-09
AR002030A1 (es) 1998-01-07
US6337324B1 (en) 2002-01-08
HK1004368A1 (en) 1998-11-27
KR19980701959A (ko) 1998-06-25
EP1419803B1 (en) 2009-01-21
HRP960034A2 (en) 1997-10-31
CN1179718A (zh) 1998-04-22
EP0809498A1 (en) 1997-12-03
CA2211389C (en) 2007-11-20
KR100431042B1 (ko) 2004-06-16
MA23800A1 (fr) 1996-10-01
PT809498E (pt) 2004-06-30
JP2007284452A (ja) 2007-11-01
DE69637828D1 (de) 2009-03-12
NO973612L (no) 1997-09-26
IL116913A0 (en) 1996-05-14
WO1996024355A1 (en) 1996-08-15
YU7296A (sh) 1998-08-14

Similar Documents

Publication Publication Date Title
FR10C0038I2 (zh)
DE69638352D1 (zh)
DE69637714D1 (zh)
BR122012014331A2 (zh)
BRPI9612258B1 (zh)
BRPI9612138B1 (zh)
ECSDI950232S (zh)
DK143195A (zh)
CH0741373H1 (zh)
DK0727898T3 (zh)
ECSDI950233S (zh)
BR7501503U (zh)
BR7502120U (zh)
ECSDI950231S (zh)
ECSDI950230S (zh)
ECSDI950229S (zh)
ECSDI950223S (zh)
DK126096A (zh)
CN3033771S (zh)
CN3036463S (zh)
CN3032568S (zh)
CN3032692S (zh)
CN3033225S (zh)
CN3033635S (zh)
CN3031926S (zh)